Calliditas Therapeutics has publicly filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of its American Depositary Shares, representing Calliditas’ common shares, in the United States and a concurrent private placement of its common shares in Europe and other countries outside of the United States to certain qualified investors.
The company has applied to list the ADSs on the Nasdaq Global Market under the ticker symbol “CALT”. The company’s common shares are listed on Nasdaq Stockholm under the symbol “CALTX”. The number of ADSs and common shares that may be offered as well as the number of common shares, including common shares underlying the ADSs, that may be issued and the price for such instruments, have not yet been determined.
A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. The offering will be made only by means of a prospectus approved by the SEC. Even if the Board of Directors determines to proceed with the potential Global Offering and listing, the offering may not be consummated. The potential Global Offering will not commence until the SEC and Nasdaq Global Market complete their respective review processes, and any such offering remains subject to market conditions and investor demand. The company intends to maintain the listing of its common shares on Nasdaq Stockholm. Should Calliditas’ Board of Directors resolve to issue common shares for the purposes of the proposed Global Offering, a Swedish prospectus solely for the purpose of admitting underlying common shares, as well as common shares for the contemplated private placement in Europe, on Nasdaq Stockholm, will be registered with the Swedish Financial Supervisory Authority.
Photo of Renée Aguiar-Lucander, CEO at Calliditas